You just read:

Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease

News provided by

Resverlogix Corp.

28 Aug, 2012, 13:00 BST